Given the alterations in AKT, AMPK, p42/44MAPK and PKC signaling with CCL2 and HGF treatment, we determined the contributions of these pathways to CCL2 and HGF-mediated metabolism in breast cancer cells. This evidence concerns the gene PRRT2 and breast carcinoma.